Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329082 · ClinicalTrials.gov registry record · Phase 2
Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00329082 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 25 participants.
The verdict
NCT00329082, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
To study the safety of LY2062430 in patients with mild-to-moderate Alzheimer's disease and in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG LY2062430
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00329082
The ClinicalTrials.gov registry entry for NCT00329082 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00329082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00329082 about?
NCT00329082 is a clinical study titled "Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers". To study the safety of LY2062430 in patients with mild-to-moderate Alzheimer's disease and in healthy volunteers.
What is the current status of trial NCT00329082?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2006-05. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00329082?
The interventions under investigation include: Placebo (DRUG), LY2062430 (DRUG).
Who is sponsoring clinical trial NCT00329082?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.